[Gene therapy for Parkinson's disease].
Identifieur interne : 000F71 ( PubMed/Curation ); précédent : 000F70; suivant : 000F72[Gene therapy for Parkinson's disease].
Auteurs : V. Fraix [France]Source :
- La Revue de medecine interne [ 0248-8663 ] ; 2004.
English descriptors
- KwdEn :
- MESH :
- chemical , biosynthesis : Dopamine.
- chemical , genetics : Dopamine, Nerve Growth Factors.
- chemical , pharmacology : Nerve Growth Factors.
- genetics : Parkinson Disease.
- pathology : Neurons.
- therapy : Parkinson Disease.
- Genetic Therapy, Humans.
Abstract
Parkinson's disease is a progressive neurodegenerative disorder whose main histopathological feature is the loss of dopaminergic neurons in the pars compacta of the substantia nigra with secondary striatal dopaminergic insufficiency. Treatment relies on medical therapy, using levodopa and dopaminergic agonists. However, the development of treatment complications, including motor fluctuations and levodopa-induced dyskinesia, led to the development of alternative therapeutical strategies such as deep brain stimulation and gene therapy.
DOI: 10.1016/j.revmed.2004.03.005
PubMed: 15219371
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001012
Links to Exploration step
pubmed:15219371Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Gene therapy for Parkinson's disease].</title><author><name sortKey="Fraix, V" sort="Fraix, V" uniqKey="Fraix V" first="V" last="Fraix">V. Fraix</name><affiliation wicri:level="1"><nlm:affiliation>Inserm U318, université Joseph-Fourier, Grenoble, France. valerie.fraix@ujf-grenoble.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm U318, université Joseph-Fourier, Grenoble</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15219371</idno><idno type="pmid">15219371</idno><idno type="doi">10.1016/j.revmed.2004.03.005</idno><idno type="wicri:Area/PubMed/Corpus">001012</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001012</idno><idno type="wicri:Area/PubMed/Curation">000F71</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F71</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Gene therapy for Parkinson's disease].</title><author><name sortKey="Fraix, V" sort="Fraix, V" uniqKey="Fraix V" first="V" last="Fraix">V. Fraix</name><affiliation wicri:level="1"><nlm:affiliation>Inserm U318, université Joseph-Fourier, Grenoble, France. valerie.fraix@ujf-grenoble.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm U318, université Joseph-Fourier, Grenoble</wicri:regionArea></affiliation></author></analytic><series><title level="j">La Revue de medecine interne</title><idno type="ISSN">0248-8663</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine (biosynthesis)</term><term>Dopamine (genetics)</term><term>Genetic Therapy</term><term>Humans</term><term>Nerve Growth Factors (genetics)</term><term>Nerve Growth Factors (pharmacology)</term><term>Neurons (pathology)</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease (therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Dopamine</term><term>Nerve Growth Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Nerve Growth Factors</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Genetic Therapy</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease is a progressive neurodegenerative disorder whose main histopathological feature is the loss of dopaminergic neurons in the pars compacta of the substantia nigra with secondary striatal dopaminergic insufficiency. Treatment relies on medical therapy, using levodopa and dopaminergic agonists. However, the development of treatment complications, including motor fluctuations and levodopa-induced dyskinesia, led to the development of alternative therapeutical strategies such as deep brain stimulation and gene therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15219371</PMID><DateCreated><Year>2004</Year><Month>06</Month><Day>28</Day></DateCreated><DateCompleted><Year>2004</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0248-8663</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>7</Issue><PubDate><Year>2004</Year><Month>Jul</Month></PubDate></JournalIssue><Title>La Revue de medecine interne</Title><ISOAbbreviation>Rev Med Interne</ISOAbbreviation></Journal><ArticleTitle>[Gene therapy for Parkinson's disease].</ArticleTitle><Pagination><MedlinePgn>524-7</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Parkinson's disease is a progressive neurodegenerative disorder whose main histopathological feature is the loss of dopaminergic neurons in the pars compacta of the substantia nigra with secondary striatal dopaminergic insufficiency. Treatment relies on medical therapy, using levodopa and dopaminergic agonists. However, the development of treatment complications, including motor fluctuations and levodopa-induced dyskinesia, led to the development of alternative therapeutical strategies such as deep brain stimulation and gene therapy.</AbstractText><AbstractText Label="EXEGESIS" NlmCategory="METHODS">Current gene therapy models for Parkinson's disease have focused on two strategies. The first one is the replacement of biosynthetic enzymes for dopamine synthesis and the second consists in the addition of neurotrophic factors for protection and restoration of dopaminergic neurons.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Neuroprotection and restoration of the nigrostriatal pathway are important issues for future genetic treatment strategies for Parkinson's disease and could include, in addition to neurotrophic factors, genes to prevent apoptosis or detoxify free radical species.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fraix</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Inserm U318, université Joseph-Fourier, Grenoble, France. valerie.fraix@ujf-grenoble.fr</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Thérapie génique et maladie de Parkinson.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Med Interne</MedlineTA><NlmUniqueID>8101383</NlmUniqueID><ISSNLinking>0248-8663</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>14</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>01</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>03</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>8</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15219371</ArticleId><ArticleId IdType="doi">10.1016/j.revmed.2004.03.005</ArticleId><ArticleId IdType="pii">S0248866304001079</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F71 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000F71 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:15219371
|texte= [Gene therapy for Parkinson's disease].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15219371" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |